Home > Neurology > AAN 2022 > Multiple Sclerosis > Sustained long-term efficacy and safety of satralizumab in NMOSD

Sustained long-term efficacy and safety of satralizumab in NMOSD

Presented By
Prof. Jeffrey Bennett, University of Colorado Hospital, CO, USA
Presented by
Jeffrey Bennett University of Colorado Hospital
AAN 2022
Phase 3, SAkuraSky; SAkuraStar
The favourable efficacy and safety profile of satralizumab was sustained with long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) in the open-label extensions (OLE) of the controlled SAkuraSky and SAkuraStar trials. High proportions of AQP4-IgG+ patients remained free from relapse and worsening disability after 3.7 years. Safety was also sustained over a median exposure of 4 years. Two separate presentations assessed the long-term efficacy and safety, respectively, of satralizumab in patients with aquaporin-4-IgG-seropositive (AQP4-IgG+) NMOSD. Prof. Jeffrey Bennett (University of Colorado Hospital, CO, USA) presented the efficacy results [1]. He explained that participants from the SAkuraySky (NCT02028884) and SAkuraStar (NCT02073279) trials cou...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on